Reducing hospital admissions for COPD patients using home nursing interventions

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on patients with stage 4 chronic obstructive pulmonary disease (COPD) and aims to reduce hospital admissions through multiple nursing interventions conducted via phone calls and health education. Participants will receive follow-up calls shortly after hospital discharge to address their health concerns and monitor their condition. The intervention includes the use of a mobile application for communication and support, ensuring patients have access to necessary information about their illness and treatment. The goal is to improve the quality of life for COPD patients and decrease the frequency of acute exacerbations that lead to hospitalization.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Being diagnosed with stage 4 (group D) COPD according to GOLD criteria
* Being 18 years or older,
* Having a video computer, tablet or phone,
* Having an internet connection at home or on the phone,
* Residing in the city centre of Konya,
* Not having a communication problem, such as an inability to understand/speak Turkish, that would prevent participation in the research,
* Being literate,
* Using an oxygen concentrator at home.

Exclusion Criteria:

* Being illiterate,
* Being diagnosed with first, second and third-stage COPD according to GOLD criteria,
* Having another lung disease in addition to COPD (Lung cancer-Asthma, etc.),
* Having physical and/or mental disabilities,
* Being visually impaired and/or hearing impaired,
* Having a communication problem that prevents participation in the research, such as an inability to understand/speak Turkish,
* Having been diagnosed with Covid-19 or having had it in the past,
* Having a psychiatric disease

Where it's running

• Selçuk Tıp Fakültesi Hastanesi
  Konya, Turkey (Türkiye) Recruiting

Study contacts

• Principal investigator: Di̇lek Ci̇ngi̇l — https://erbakan.edu.tr/hemsirelikfak
• Study coordinator: Hasan Bakir
• Email: smhasanbakir@gmail.com
• Phone: 05055346870

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ensa?fentrine to help prevent COPD flare-ups in adults on standard care

  This study tests whether ensifentrine (MK-5884) can help prevent moderate or severe COPD exacerbations compared with placebo in adults already receiving standard COPD treatment.

  Recruiting at 7 sites Phase 3 Merck Sharp & Dohme LLC · Hialeah Gardens, Florida and 6 other locations · NCT07874815

• GSK Investigational Medicine GSK3862995B: two formulations in healthy adults

  This early-phase study tests two formulations of GSK3862995B in healthy adults to see how the body handles the drug and whether it is safe and tolerable.

  Recruiting Phase 1 GlaxoSmithKline · Cambridge · NCT07789899

• GSK5784283 added to standard COPD therapy vs placebo in moderate to very severe COPD

  This study tests whether adding GSK5784283 to current COPD treatment reduces the rate of COPD flare-ups in adults with eosinophilic COPD and a history of exacerbations.

  Recruiting at 7 sites Phase 3 GlaxoSmithKline · Doral, Florida and 6 other locations · NCT07780669

• GSK5784283 added to standard COPD care versus placebo in adults with moderate to very severe COPD

  This study tests whether adding GSK5784283 to a patient’s current COPD treatment helps reduce COPD flare-ups compared with a placebo in adults with eosinophilic COPD and a history of frequent exacerbations.

  Recruiting at 8 sites Phase 3 GlaxoSmithKline · Cape Coral, Florida and 7 other locations · NCT07780656

• Brenipatide for adults with moderate-to-severe COPD

  This study tests different doses of Brenipatide to see if it is safe and effective for adults with moderate-to-severe COPD, compared with placebo.

  Recruiting at 69 sites Phase 2 Eli Lilly and Company · Birmingham, Alabama and 126 other locations · NCT07759245

• Early depemokimab treatment for COPD with type 2 (eosinophilic) inflammation

  This trial will test whether adding depemokimab early to standard care helps adults with moderate-to-severe COPD who have type 2 (eosinophilic) inflammation.

  Recruiting at 121 sites Phase 3 GlaxoSmithKline · Newport Beach, California and 120 other locations · NCT07177339

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.